Aurealis Therapeutics Accelerates Oncology Program: First abstract published at ASCO as the team prepares for Annual Meeting in Chicago
Aurealis Therapeutics, a synthetic biology company developing ground-breaking cell and gene therapies for unmet medical needs, accelerates its expansion in Oncology with its first-in-class four-in-one Bacterial Cell and Gene Therapy AUP-55. The company’s first abstract, Effect of multi-targeting bacterial gene therapy on tumor regression and survival in mouse models of ovarian and intraperitoneal cancer, has […]
Aurealis Therapeutics announces approval of multi-center, randomized, placebo-controlled diabetic foot ulcer Phase 2 study to start May 2023 in Italy, Germany and Poland.
Aurealis Therapeutics, a Swiss-Finnish private clinical-stage synthetic biology company focusing on the development of lactic acid bacteria -based GMO cell and gene therapies, announces clinical trial application (CTA) approval of a multi-center, randomized, placebo-controlled diabetic foot ulcer (DFU) Phase 2 study to start this month in Italy, Germany, and Poland. The Global Coordinating Investigator of […]
Aurealis Therapeutics will be presenting during the European Wound Management Association (EWMA) 2023 Conference
Aurealis Therapeutics is excited to sponsor the European Wound Management Association (EWMA) 2023 Conference taking place in Milan, Italy from 3-5 May 2023. Our CEO Juha Yrjänheikki, COO Laurent Décory, and CMO Haritha Samaranayake and will be attending the conference. We will actively participate several parts of the event: On the 4th of May, Laurent Décory, COO […]
Aurealis Therapeutics is attending the Swiss Biotech Day 2023
Juha Yrjänheikki (CEO) and Laurent Décory (COO) will be attending the Swiss Biotech Day 2023 which will take place from 24-25 April in Basel, Switzerland. This will be a fantastic opportunity to meet investors and discuss potential partnerships with pharma companies. The Swiss Biotech Day is one of the leading biotechnology conferences in Europe offering […]
Aurealis Therapeutics Raises $10 Million in an Oversubscribed Series A Financing to Accelerate Phase 2 Clinical Studies in Chronic Wounds and Preclinical Development in Oncology with Its First-in-Class Technology Platform

Aurealis Therapeutics, a synthetic biology company developing ground-breaking cell and gene therapies for